Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert I Nicholson

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibitionJoan Albanell, Federico Rojo, Steve Averbuch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combinationRobert I Nicholson, Iain R Hutcheson, Janice M Knowlden, et al.
Nature|November 14, 2008
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifenAntoni Hurtado, Kelly A Holmes, Timothy R Geistlinger, et al.
Breast Cancer Research : BCR|March 19, 2013
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancerJohn F R Robertson, J Michael Dixon, D Mark Sibbering, et al.
Journal of Medicinal Chemistry|February 3, 2006
New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studiesGabriella De Martino, Michael C Edler, Giuseppe La Regina, et al.
Plos One|July 19, 2012
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerAndrew Stone, Fatima Valdés-Mora, Julia M W Gee, et al.
Hormone Molecular Biology and Clinical Investigation|May 12, 2015
Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistanceJulia M W Gee, Robert I Nicholson, Denise Barrow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotypeEmad A Rakha, Maysa E El-Sayed, Andrew R Green, et al.
Breast Cancer Research and Treatment|January 31, 2012
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II studyIrene Kuter, Julia M W Gee, Roberto Hegg, et al.
Nature Communications|July 15, 2015
DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancerAndrew Stone, Elena Zotenko, Warwick J Locke, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibitionJoan Albanell, Federico Rojo, Steve Averbuch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combinationRobert I Nicholson, Iain R Hutcheson, Janice M Knowlden, et al.
Nature|November 14, 2008
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifenAntoni Hurtado, Kelly A Holmes, Timothy R Geistlinger, et al.
Breast Cancer Research : BCR|March 19, 2013
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancerJohn F R Robertson, J Michael Dixon, D Mark Sibbering, et al.
Journal of Medicinal Chemistry|February 3, 2006
New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studiesGabriella De Martino, Michael C Edler, Giuseppe La Regina, et al.
Plos One|July 19, 2012
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerAndrew Stone, Fatima Valdés-Mora, Julia M W Gee, et al.
Hormone Molecular Biology and Clinical Investigation|May 12, 2015
Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistanceJulia M W Gee, Robert I Nicholson, Denise Barrow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotypeEmad A Rakha, Maysa E El-Sayed, Andrew R Green, et al.
Breast Cancer Research and Treatment|January 31, 2012
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II studyIrene Kuter, Julia M W Gee, Roberto Hegg, et al.
Nature Communications|July 15, 2015
DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancerAndrew Stone, Elena Zotenko, Warwick J Locke, et al.
Pageof 8